MedTrace Logo

PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims

NCT02520726 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-04-10

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled study to determine whether administration of sertraline to patients who exhibit acute stress disorder secondary to severe burns can contribute to the prevention of post-traumatic stress disorder (PTSD).

Conditions

  • Post-traumatic Stress Disorder

Interventions

DRUG

Sertraline

\< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.

DRUG

Placebo oral capsule

Matched encapsulated placebo from 1-4 capsules daily

Sponsors & Collaborators

Principal Investigators

  • Brent M Kious, MD PhD · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02520726 on ClinicalTrials.gov